Cell Culture Media Market Size & Share 2026-2035

Cell Culture Media Market Size

The global cell culture media market was valued at USD 3.9 billion in 2025. The market is expected to grow from USD 4.3 billion in 2026 to reach USD 10.8 billion in 2035, growing at a CAGR of 10.8% over the analysis period, as per the latest report published by Global Market Insights, Inc.

The global cell culture media market is experiencing dynamic growth driven by the rising global prevalence of chronic diseases, such as cancer, diabetes, and autoimmune diseases, which fuel the demand for cell-based research therapies.

In addition, the ongoing advancements in cell culture technologies, such as the development of serum-free and chemically defined media formulations, have improved the efficiency, reproducibility, and scalability of cell culture. For instance, in July 2023, Lonza launched the TheraPRO CHO Media System, a new cell culture platform that simplifies processes and optimizes productivity and protein quality when used with GS-CHO cell lines. Such advancements drive the adoption of cell culture media in regenerative medicine and pharmaceutical applications, which is anticipated to accelerate market growth.

Between 2022 and 2024, the global cell culture media market witnessed steady growth, supported by the rapid expansion of the biopharmaceutical and biotechnology sectors. The market reached an estimated value of USD 3.7 billion in 2024, growing from USD 3.3 billion in 2022, reflecting robust demand for cell-based research, vaccine production, and biologics manufacturing. For instance, in 2025, the FDA approved approximately 12-18 new biologics (including mAbs, ADCs, and proteins), representing about 26% of all new drug approvals. Similarly, as of April 2024, 32 gene therapies have been approved globally for clinical use, and more than 2,000 gene therapies are in various stages of development. This growing biologics pipeline, coupled with the rapid progression of cell and gene therapy, continues to drive demand for high-quality media. Additionally, the shift toward serum-free and specialty media, which now accounts for a substantial share of new product adoption is further accelerated market expansion.

Cell culture media, also known as growth media, is a broad term that encompasses any gel or liquid designed to support cellular growth in an artificial environment. It provides the nutrients necessary for cell cultures to survive and proliferate. The cell culture media industry refers to the global market involved in producing and supplying these nutrient-rich solutions, which support the growth, maintenance, and differentiation of cells in laboratory settings. Key players include Thermo Fisher Scientific, Merck KGaA, Cytiva (Danaher), Sartorius, FUJIFILM Irvine Scientific (FUJIFILM Holdings), Corning, and Lonza Group, among others. These players compete through strong product portfolios, global reach, and ongoing innovation in serum-free and specialized media, while expanding capacity and partnerships to support growing demand in biologics and advanced therapies.

Cell Culture Media Market Trends

• One of the major trends in the cell culture media industry is the growing transition from serum-based media to serum-free and chemically defined media. This is due to the increasing requirement for higher reproducibility, lower contamination risk, and regulatory compliance. Biopharmaceutical manufacturers are increasingly adopting defined media to ensure batch-to-batch consistency and meet stringent quality standards, particularly in biologics and vaccine production.
• The growth of cell and gene therapies (CGTs) is also having a major impact on the growth of specialized and high-performance media. This is due to the fact that cell and gene therapies require a high level of optimization in their formulation to support delicate cell types such as stem cells and viral vectors. As the CGT pipeline grows globally, there is an increasing need to develop customized media solutions to meet specific therapeutic needs, which is boosting the demand for advanced cell culture media.
• In addition, the rise in outsourcing to contract development and manufacturing organizations (CDMOs) is driving large-scale demand for cell culture media. CDMOs require consistent, scalable, and regulatory-compliant media solutions to support multiple clients and projects. Simultaneously, rising global investments in biomanufacturing infrastructure, particularly in emerging markets, are further fuelling the need for reliable and high-quality media supply.
• Lastly, the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders, is expected to significantly drive demand in the cell culture media market.
• For instance, as per the data published by the American Cancer Society, in January 2024, 2,001,140 new cancer cases and 611,720 cancer deaths were projected to occur in the U.S. Cancer mortality continued to decline through 2021. Moreover, the report published by the International Agency for Research on Cancer (IARC) predicts that the global burden of cancer will continue to rise, with over 35 million new cancer cases expected by 2050, representing a 77% increase from the 20 million cases recorded in 2022. This sharp rise underscores the growing need for advanced treatment options and continuous medical innovation.
• As cancer cases increase, there will be a greater demand for effective treatments, including cell-based therapies like CAR-T cell therapies and other immunotherapies. These therapies rely on high-quality, specialized cell culture media to support cell growth, viability, and function, making the development and production of advanced cell culture media crucial for their success.

Cell Culture Media Market Analysis

Based on the product type, the market is classified into serum-free media, specialty media, chemically defined media, stem cell culture media, and other product types. The serum-free media segment dominated the market with a revenue of USD 2.1 billion in 2025. The segment is further classified into CHO media, HEK 293 media, BHK media, VERO cell media, insect cell media, immune cell media, and other serum-free media.

• The serum-free media segment holds a significant share in the global cell culture media market, driven by its advantages such as consistency, safety, and regulatory compliance.
• Unlike traditional serum-based media, serum-free formulations eliminate variability associated with animal-derived components, ensuring reproducible cell growth and improving product quality, which is critical for biologics and vaccine manufacturing.
• Further, their widespread adoption is supported by the increasing use of monoclonal antibodies and cell-based therapies, where contamination risks must be minimized.
• Additionally, regulatory agencies increasingly favor defined media systems, accelerating the shift toward serum-free alternatives and reinforcing their dominant position in the market.
• On the other hand, the specialty media segment held the second-largest market share of 18.3% in 2025, driven by its increasing use in targeted applications requiring high selectivity and performance, particularly in advanced research and diagnostic workflows.

Based on the application, the global market is classified into biopharmaceutical production, diagnostics, drug screening and development, tissue engineering and regenerative medicine, research purpose, and other applications. The biopharmaceutical production segment dominated the market with a market share of 30.8% in 2025.

• The biopharmaceutical production segment holds a prominent share in the cell culture media market, owing to the rapid growth of the biopharmaceutical industry, coupled with high adoption of biologics, including monoclonal antibodies, vaccines, recombinant protein production, cell therapy, and gene therapy.
• For instance, in 2025, the U.S. Food and Drug Administration (FDA) approved 44 new drugs, of which biologics accounted for 25% of approvals, including nine monoclonal antibodies (mAbs), two antibody–drug conjugates (ADCs), and one fusion protein, with cancer remaining the primary therapeutic focus.
• Moreover, the rising incidence of chronic conditions, coupled with the increasing need for targeted therapies, has led to the rapid development and commercialization of biologics, thereby fueling the growth of the cell culture media market.
• In addition, advancements in bioprocessing technology, the transition towards commercial-scale production, and the increasing acceptance of single-use bioreactors have also supported the market growth.
• The tissue engineering and regenerative medicine segment, on the other hand, is expected to grow at a CAGR of 11.1% over the forecast period, owing to the increasing investments in stem cell research, rising demand for advanced therapies for chronic diseases, and continuous advancements in biomaterials and 3D cell culture technologies.

Based on the end use, the cell culture media market is classified into pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, research & academic institutes, and other end users. The pharmaceutical and biotechnology companies’ segment is expected to reach USD 4 billion by 2035, maintaining its dominance due to their role in the development and manufacturing of biologics, vaccines, and cell-based therapies.

• These companies utilize advanced cell culture techniques to produce high-quality therapeutic products, including monoclonal antibodies, gene therapies, and regenerative treatments.
• Advancements in genomics and targeted therapies have led to an increased demand for personalized medicine, which in turn drives the need for specialized cell culture media in drug development and production.
• As the focus on precision medicine grows, the requirement for media that supports the optimal growth, viability, and function of cells becomes even more critical.
• Moreover, both sectors maintain a strong emphasis on research and development, which translates into significant investments in the optimization of cell culture media.

North America Cell Culture Media Market

In 2025, North America secured a substantial market share of 39% in the global cell culture media industry and is expected to dominate throughout the forecast period.

• North America's biotechnology and pharmaceutical sectors maintain a strong global position through advanced research infrastructure and substantial life sciences investments.
• In addition, high funding for biopharmaceutical research and several initiatives aid in market growth. The U.S. government's funding of biomedical research through the National Institutes of Health (NIH) serves as a primary driver of this growth.
• For example, the National Institutes of Health (NIH) reached an annual budget of approximately USD 48 billion in fiscal year 2024, supporting over 300,000 research personnel and nearly 50,000 competitive grants. This funding facilitates healthcare and biotechnology breakthroughs, fostering the development of new therapies, medical technologies, and cell-based treatments.
• Also, the increasing demand for targeted and personalized treatments has elevated the need for specialized cell culture media, thus driving the regional market growth.

The U.S. cell culture media market was valued at USD 1.15 billion and USD 1.22 billion in 2022 and 2023, respectively. The market size reached USD 1.37 billion in 2025, growing from USD 1.28 billion in 2024.

• The U.S. holds a significant share in the market due to the robust biopharmaceutical sector in the country, coupled with a strong presence of the biotech industry and the research infrastructure.
• The country also benefits from the strong R&D investments. For instance, as per the Pharmaceutical Research and Manufacturers of America (PhRMA) trade group, in 2024, the research and development (R&D) expenditure of its member companies reached USD 104 billion worldwide.
• Furthermore, a high number of biologics approvals in the country, widespread adoption of advanced bioprocessing techniques, and support from regulatory authorities have further strengthened the position of the U.S. market.

Europe Cell Culture Media Market

Europe contributes substantially to the global cell culture media industry, owing to its well-established biopharmaceutical manufacturing industry, research infrastructure, and regulatory environment.

• The region also benefits from considerable investments in life science research and development, where Germany, UK, and France are key markets for biotechnology and pharmaceutical research and development.
• Furthermore, as per Pharmaphorum, as of 2025, European companies possess 25% of the global biopharma pipeline, thus contributing to continuous demand for cell culture media in this region.
• The regulatory support provided by regulatory authorities such as the European Medicines Agency, along with rising interest in biosimilar development, cell and gene therapies, and research and development collaborations, also contributes to market growth in this region.

Germany holds a prominent position in the European cell culture media market, owing to its well-established biotechnology industry, manufacturing infrastructure, and research intensity.

• Germany has a robust biotechnology sector, with over 798 dedicated biotechnology companies operating as of 2023. The country also features a vast, well-funded research landscape containing over 1,000 public research institutions.
• In addition, as per Germany Trade & Invest (GTAI), the country is the second-largest producer of biopharmaceuticals approved in the European Union, behind the U.S.
• Thus, the country holds a leading position as a hub for the development and manufacturing of biologics, thereby driving the demand for cell culture media.

• Additionally, continuous investments in biopharmaceutical manufacturing, increasing clinical trials activity, and strong regulatory alignment further reinforce Germany’s dominance in the regional market.

Asia Pacific Cell Culture Media Market

The Asia Pacific market is anticipated to witness robust growth at a 11.6% CAGR over the analysis period.

• Asia Pacific represents a major and rising market for cell culture media, driven by the rapid growth of biopharmaceutical manufacturing in the region, strong clinical trial activity, and growing investments in the life sciences industry.
• For instance, the Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during this period.
• In addition, the region is witnessing rapid growth as a biologics manufacturing and outsourcing hub, driven by cost advantages and a large patient population.
• Furthermore, advancements in research facilities, government initiatives to support the biotechnology industry, and the adoption of advanced bioprocessing technology are fueling the regional growth.

China holds a dominant share in the Asia Pacific cell culture media market owing to the rapidly developing biopharmaceutical industry in the country, favorable government policies, and increasing investments in the field of biotechnology and life sciences.

• The country has emerged as a global hub for biologics manufacturing and contract research, supported by cost advantages and a large patient population.
• Additionally, the presence of a large number of domestic biopharma companies, the continuous expansion of manufacturing facilities, and favorable regulatory reforms are further accelerating market growth.

Latin America Cell Culture Media Market

Brazil has a considerable market share in the Latin America cell culture media industry.

• The country’s well-established pharmaceutical market, rapidly developing biotechnology industry, and increasing investments in healthcare research activities are key factors driving market growth.
• In addition, Brazil is witnessing an increase in clinical trial activities and biologics production, owing to its large population and developing research infrastructure, in turn driving the demand for cell culture media.
• Furthermore, favorable government initiatives to strengthen domestic biopharma manufacturing, coupled with rising funding and investments, are further driving the market growth.

Middle East & Africa Cell Culture Media Market

South Africa holds a significant share of the Middle East & Africa cell culture media industry.

• South Africa is witnessing rapid growth in the cell culture media market owing to the relatively advanced healthcare infrastructure and the emerging biotechnology research sector.
• The country contributes significantly to the clinical trials carried out in Africa, with 90% of these trials in Africa being conducted in just two countries: Egypt and South Africa. Thus, South Africa acts as a prominent location for drug development activities, thereby boosting the need for cell culture media.
• Moreover, the growing government focus on enhancing domestic pharmaceutical manufacturing, along with escalating investments in research and development institutions, and the increasing partnerships with international biopharmaceutical companies, all contribute to the growth of the market.

Cell Culture Media Market Share

The key players in the global cell culture media industry include Thermo Fisher Scientific, Merck KGaA, Cytiva (Danaher Corporation), FUJIFILM Irvine Scientific (FUJIFILM Holdings), and Sartorius. The top 5 players collectively hold ~78.1% of the global market. These players dominate the market through strategic investments in R&D, partnerships, and acquisitions, with a strong focus on serum-free and chemically defined media, as well as customized solutions for biopharmaceutical production. Meanwhile, emerging and regional companies are gaining traction by offering cost-effective alternatives and localized manufacturing. Strategic initiatives such as mergers and acquisitions, partnerships with biopharma companies, and capacity expansions are common, as companies aim to strengthen their market position and cater to the growing demand for biologics and advanced therapies.

Cell Culture Media Market Companies

Prominent players operating in the cell culture media industry are as mentioned below:

• ACROBiosystems
• Biowest
• Cellplus Bio
• Corning
• Cytiva
• Elabscience
• Eminence Scientific
• FUJIFILM Irvine Scientific
• JSBio
• Lonza
• Shanghai Mediumbank Biotechnology
• Merck
• Miltenyi Biotec
• OPM Biosciences
• ProBio
• PromoCell
• Quacell Biotechnology
• Sartorius
• Shanghai BioEngine
• Shanghai Basal Media
• Sino Biological
• Suzhou Womei
• Thermo Fisher Scientific

• Thermo Fisher Scientific

Thermo Fisher Scientific is a leading player in the cell culture media market, with a comprehensive portfolio spanning classical media, specialty media, and advanced formulations such as serum-free and chemically defined media. The company leverages its strong global manufacturing footprint and well-established brands (e.g., Gibco) to serve biopharmaceutical production, research, and clinical applications.

• Merck

Merck KGaA is a key player in the cell culture media market, operating through its Life Science segment. The company offers a broad portfolio of cell culture media, including classical, specialty, and chemically defined formulations, catering to both research and biopharmaceutical manufacturing applications. With its global manufacturing network, strong R&D capabilities, and strategic investments in bioprocessing, the company continues to strengthen its position in the market.

The cell culture media market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Serum-free media
  • CHO media
  • HEK 293 media
  • BHK media
  • VERO cell media
  • Insect cell media
  • Immune cell media
  • Other serum-free media
• Specialty media
• Chemically defined media
• Stem cell culture media
• Other product types

Market, By Application

• Biopharmaceutical production
  • Monoclonal antibodies
  • Vaccine production
  • Other biopharmaceutical productions
• Diagnostics
• Drug screening and development
• Tissue engineering and regenerative medicine
• Research purpose
• Other applications

Market, By End Use

• Pharmaceutical and biotechnology companies
• Hospitals and diagnostic laboratories
• Research and academic institutes
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE